Clinical trial NCT04746209: Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Official title: Alpha/Beta T-cell and B-cell Depleted Allogeneic Transplantation (IDE 13641) Followed by Blinatumomab Therapy for High-Risk B-Acute Lymphoblastic Leukemia: A Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: B-cell Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
B-Cell ALL, Childhood
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
Collaborators: name: Amgen
name: University of Wisconsin, Madison
First posted: 2021-02-09
Enrollment: 25
Sex: ALL
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.

Detailed description: This trial evaluates the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce the risk of leukemia relapse following HCT to improve post-HCT outcomes. The investigators will also utilize an alpha-beta T-cell and B-cell depleted graft to reduce the risk of GVHD along with a reduced intensity conditioning regimen without the use of TBI in patients who are minimal residual disease (MRD) negative using high throughput sequencing (HTS) prior to HCT. For those patients who remain HTS-MRD positive, a myeloablative conditioning regimen will be utilized, also followed by blinatumomab. This multi-institutional pilot study will be limited to 25 (estimated 10-15 per stratum) evaluable children, adolescents and young adults with B-ALL, that have experienced a relapse or have high-risk disease.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of B-ALL with no evidence of minimal residual disease in the bone marrow by multi-parameter flow cytometry (FC-MRD negative, \<0.01%) and meet at least one of the following:

  1. In remission after first relapse or greater (≥ CR2)
  2. Very-high risk biology ALL that is proceeding to HCT in first remission (e.g. Induction failure, Severe-hypodiploidy, Ph-like ALL)
  3. First remission with persistent disease identified as end of consolidation (EOC) MRD \> 0.01%.
* Patients must have an available unrelated or haploidentical donor
* Age ≤ 25 years at time of study enrollment
* Karnofsky Performance Status ≥ 60% for patients 16 years and older and Lansky Play Score ≥ 60 for patients under 16 years of age
* Have acceptable organ function as defined within 14 days of study registration: Renal: creatinine clearance or radioisotope GFR ≥ 60 mL/min/1.73m2 Hepatic: ALT \< 5 x upper limit of normal (ULN) and total bilirubin ≤ 3 mg/dL Cardiac: left ventricular ejection fraction ≥ 40% by ECHO/MUGA Pulmonary: No evidence of dyspnea at rest. No supplemental oxygen requirement. If measured, carbon monoxide diffusion capacity (DLCO) \> 50%. Central Nervous System: Based on clinical exam, no concern for/evidence of active CNS infection. Patients with fully treated prior CNS infections are eligible. Patients with seizure disorders may be enrolled if seizures are well-controlled on anticonvulsant therapy.
* Patients who have experienced their relapse after HCT are eligible, provided they have no evidence of acute or chronic Graft-versus-Host Disease (GVHD) and are off all transplant immune suppression therapy for at least 7-days (e.g. steroids, cyclosporine, tacrolimus). Steroid therapy for non-GVHD and/or non-leukemia therapy is acceptable.
* Immunotherapy: At least 42 days after the completion of any type of immunotherapy aside from blinatumomab (e.g. tumor vaccines or CAR T-cell therapy).
* XRT: Cranial or craniospinal XRT is prohibited during protocol therapy. ≥ 90 days must have elapsed if prior TBI, cranial or craniospinal XRT
* Sexually active females of child bearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment and for 2 months after the completion of blinatumomab therapy. Sexually active men must agree to use barrier contraceptive for the duration of treatment and for 2 months after the completion of blinatumomab therapy.
* Voluntary written consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
* All patients enrolled in this study must have been enrolled in the Blinatumomab Bridging Therapy (BBT) Trial

Exclusion Criteria:

* Active extramedullary disease or presence of chloromatous disease.
* Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other anti-cancer therapy for treatment of disease other than is specified in the protocol.
* Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic.
* Pregnant or lactating. The agents used in this study are known to be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. All females of childbearing potential must have a blood test or urine study within 7 days prior to registration to rule out pregnancy.
* Known allergy to any chemotherapies or targeted agents included in this protocol.
* Participating in a concomitant Phase 1 or 2 study involving treatment of disease.
* Active malignancy other than B-ALL.

Primary outcomes:
measure: Percentage of patients who are able to receive the blinatumomab infusion [Feasibility]
timeFrame: Day +100 post-HCT
Secondary outcomes:
measure: Cumulative incidence of treatment-related adverse events [Tolerability]
timeFrame: Day of HCT to Day +180 post-HCT
measure: Overall Survival
timeFrame: Day of HCT to 1 year post-HCT
measure: Disease Free Survival
timeFrame: Day of HCT to 1 year post-HCT
measure: Engraftment
timeFrame: Day +100 and +1 year post-HCT
measure: Primary Graft Failure
timeFrame: Day +28 and + 1 year post-HCT
measure: Secondary Graft Failure
timeFrame: Day +28 and +1 year post-HCT
measure: Treatment Related Mortality
timeFrame: Day of HCT to Day +100 and 1 year post-HCT
measure: Acute & Chronic GVHD
timeFrame: Day +100, +180 and 1 year post-HCT
measure: Patient Reported Outcomes
timeFrame: Baseline, Day +100, +180, +1 year post-HCT
measure: Length of Stay
timeFrame: Number of days between the day of transplantation, Day 0, and Day +180 post-HCT
measure: Persistence of Minimal Residual Disease (MRD) Negativity
timeFrame: Days +28, +100, +180 and +1 year post-HCT
measure: Relapse
timeFrame: Day of HCT to day +180 and 1 year post-HCT
Other outcomes:
measure: Analysis of immune cell phenotyping
timeFrame: Days +19, +91, +135 and +180 post-HCT
measure: Functional assessment of lymphocyte subsets
timeFrame: Days +19, +91, +135 and +180 post-HCT
measure: Serum cytokine analysis
timeFrame: Days +19, +91, +135 and +180 post-HCT
Locations:
city: Milwaukee
country: United States
facility: Children's Hospital of Wisconsin
state: Wisconsin
Study officials:
affiliation: Medical College of Wisconsin
name: Rachel Phelan, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References: